Takamichi Yanagisawa

Increased expression of human DNA repair genes, XRCC1, XRCC3 and RAD51, in radioresistant human KB carcinoma cell line N10

The radioresistant N10 and parental KB cell lines were examined for the expression of human DNA repair genes which were related to the repair of radiation-induced DNA damage by northern blot analysis using five kinds of DNA probes (XRCC1, XRCC3, XRCC5, RAD51, RAD52). In the unirradiated condition, N10 cells showed higher expression of XRCC1, XRCC3 and RAD51 mRNA than did KB cells. The X-irradiation induced a time-dependent increase in the mRNA levels of XRCC3 and RAD51 in both cell lines with a maximum at 2 h postirradiation. The XRCC1 mRNA in N10 was maintained at the same level even after irradiation, whereas that in KB was decreased after irradiation. There was no difference in the expression of XRCC5 and RAD52 mRNA between N10 and KB cells in both unirradiated and irradiated conditions. From these findings, it was suggested that XRCC1, XRCC3 and RAD51 contribute to the radioresistance in cell line N10.

Primary squamous cell carcinoma of accessory parotid gland duct epithelium: Report of a case

A rare case of primary squamous cell carcinoma surrounding Stensens duct in a 75-year-old man is presented. The tumor was a relatively well-defined, hard, subcutaneous mass, measuring 18 x 14 x 9 mm and situated in the right cheek. Microscopic examination of an excisional biopsy specimen revealed tumor cells showing squamous differentiation, a papillary growth pattern, and ductal structures with comedo necrosis. Immunohistochemical studies showed positive reactivity for KL-1 (cytokeratin, monoclonal), epithelial membrane antigen, and carcinoembryonic antigen in some tumor cells. The origin of the tumor was thought to be the accessory parotid gland duct epithelium.

Cancer pain management of adenoid cystic carcinoma patient with high dose of controlled-release Oral Morphine Sulfate at outpatient clinic.

モルヒネは強力な鎮痛効果を有し, かつ天井効果がない。したがってモルヒネは激痛を伴う進行癌患者に対して癌性疼痛が除去できるまで投与が可能である。われわれは外来にてモルヒネの大量投与を行った進行腺様嚢胞癌患者の癌性疼痛管理の1例を報告する。重大な副作用を引き起こすことなく癌性疼痛を除去するまで徐々にモルヒネを増量したところ, モルヒネの投与量は2760mg/日となり, 投与期間は21か月となった。硫酸モルヒネ徐放錠の大量投与は本患者のQOLの改善に有用であった。